Pharmacology and Mechanism of Action
CBD acts via multiple complementary pathways relevant to psychiatric and neurological conditions. Unlike conventional antipsychotics, CBD does not act as a D2 receptor antagonist. Its D2 engagement is as a partial agonist at the high-affinity D2High state, stabilising dopaminergic transmission rather than blocking it. This mechanistic distinction -- modulation rather than blockade -- is why CBD does not cause the D2 antagonist-driven side effects: extrapyramidal symptoms, tardive dyskinesia, hyperprolactinaemia, or metabolic syndrome.
| Target | Mechanism | Clinical Relevance |
|---|---|---|
| FAAH inhibition | Inhibits fatty acid amide hydrolase, elevating endogenous anandamide (AEA) and related N-acylethanolamines (OEA, PEA) | Antipsychotic (Leweke 2012: anandamide elevation correlated with PANSS improvement). Anxiolytic. Anti-inflammatory. |
| 5-HT1A partial agonism | Direct partial agonist at serotonin 5-HT1A receptors | Anxiolytic (acute anxiety reduction in human studies). Antidepressant-like effects. Sleep modulation. |
| Dopamine D2High partial agonism | Partial agonist at the high-affinity state of D2 receptors (D2High), stabilising dopaminergic transmission rather than blocking it (Seeman 2016). | Antipsychotic effect via dopamine modulation -- mechanistically analogous to aripiprazole, not to D2 antagonists (haloperidol, olanzapine). Does not cause receptor blockade-driven side effects. |
| CB1/CB2 negative allosteric modulation | Does not directly activate cannabinoid receptors. Modulates receptor conformation, reducing THC-like effects. | No psychoactive effects. No intoxication. No abuse potential (Babalonis 2017). No cannabis use disorder risk. |
| GPR55 antagonism | Antagonist at the orphan receptor GPR55 | Anticonvulsant activity. Relevant to epilepsy indications. |
| TRPV1 agonism (desensitisation) | Activates then desensitises transient receptor potential vanilloid 1 channels | Analgesic. Anti-inflammatory. Modulation of pain signalling. |
| Adenosine reuptake inhibition | Inhibits equilibrative nucleoside transporter 1, increasing extracellular adenosine | Anti-inflammatory and immunosuppressive effects. Sleep-promoting (adenosine is a somnogenic factor). |
Formulation: Why SM32300 Differs from Standard CBD
SM32300 uses a patented self-emulsifying drug delivery system (SEDDS) that forms micelles in the GI tract upon contact with aqueous media. This fundamentally alters CBD absorption compared to standard oil-based formulations.
Enhanced bioavailability
Phase 1 crossover (n=14) demonstrated that SM32300 at 600-900 mg achieves plasma AUC equivalent to ~1000 mg Epidyolex. Standard oral CBD bioavailability is ~6%; SEDDS technology increases this approximately 3-fold.
Reduced inter-subject variability
Micelle formation provides consistent absorption regardless of fed/fasted state, reducing the unpredictable PK that complicates dosing with oils.
Zero GI adverse events
In the Phase 1 trial, SM32300 produced no gastrointestinal adverse effects at 600 or 900 mg. GI events (primarily diarrhoea) are the dose-limiting toxicity for standard CBD (Chesney 2020 meta-analysis).
Precision dosing
Each softgel contains exactly 300 mg CBD, eliminating the variability inherent in syringe measurement of viscous oils.
Patient Selection: Who Should Be Considered?
SM32300 is appropriate for patients meeting the standard UK specials prescribing criteria (failed two or more licensed treatments) who fall into one or more of the following clinical categories. Click any row to expand the clinical rationale, THC cautions, and suggested starting dose.
Dosing and Titration Guide
General Principles
- Start low, titrate based on clinical response. Most patients begin at 300 mg/day (1 softgel).
- Administer with food to maximise absorption (although SEDDS technology reduces fed/fasted variability compared to standard CBD).
- For insomnia: administer 1-2 hours before bedtime.
- For anxiety/PTSD: administer in the morning, or split BID (AM/PM) for 600 mg/day.
- For schizophrenia/epilepsy: titrate to target dose over 7-14 days. Split BID for doses >600 mg/day.
- All doses are within the safety envelope established in the Phase 1 trial (up to 900 mg with zero GI AEs).
Titration Schedule
| Week | Dose | Softgels | Schedule | Assessment |
|---|---|---|---|---|
| 1-2 | 300 mg/day | 1 | 1 softgel QD (AM or PM depending on indication) | Tolerability. Baseline symptom scores. Sleep diary if insomnia. |
| 3-4 | 600 mg/day (if needed) | 2 | 1 softgel AM + 1 softgel PM (BID). Or 2 softgels QD. | Symptom response. Tolerability. LFTs if on valproate/clobazam. |
| 5+ | 900 mg/day (if needed) | 3 | 2 softgels AM + 1 softgel PM. For schizophrenia/epilepsy only. | Full clinical review. Consider steady-state PK. Monitor LFTs. |
Dose equivalence note: SM32300's enhanced bioavailability means 600 mg SM32300 achieves approximately the same plasma CBD exposure as 1000 mg Epidyolex or standard CBD oil. Published trial doses (e.g. McGuire 2018: 1000 mg) should be adjusted downward when prescribing SM32300.
Safety Profile and Monitoring
5.1 Phase 1 Safety Data
Open-label, randomised, crossover trial (n=14 healthy volunteers). SM32300 600 mg and 900 mg vs Epidyolex at 25 mg/kg (highest approved dose). University of Toronto. All participants completed all periods.
| Safety Parameter | SM32300 (600-900 mg) | Epidyolex (25 mg/kg) |
|---|---|---|
| Serious adverse events | None | None |
| GI adverse events (diarrhoea, nausea, vomiting) | None | Reported (primary AE site) |
| Somnolence | Mild, dose-related (therapeutic for insomnia) | Reported |
| Hepatotoxicity signals | None | None |
| Treatment discontinuation due to AEs | None (100% completion) | None |
5.2 Known CBD Class Effects and Monitoring
| Risk | SM32300 Relevance | Monitoring |
|---|---|---|
| Hepatotoxicity | CBD can elevate ALT/AST, particularly with co-administered valproate or clobazam. No signal in SM32300 Phase 1 at up to 900 mg. | Baseline LFTs. Repeat at 1 month and 3 months. More frequent if co-prescribed valproate or clobazam. |
| Drug interactions | CBD inhibits CYP3A4 and CYP2C19. May increase levels of clobazam (active metabolite N-desmethylclobazam), warfarin, and some SSRIs. | Review co-medications before initiation. Monitor INR if on warfarin. Monitor clobazam levels in epilepsy patients. |
| Somnolence | Dose-related. Mild in Phase 1. Therapeutically useful in insomnia patients. Advise on driving until dose is stabilised. | Counsel patients on potential drowsiness. Advise not to drive until response to medication is known. |
| THC exposure | SM32300 contains ≤0.015% THC. At 900 mg/day, maximum THC intake is <0.14 mg/day -- pharmacologically negligible and undetectable on standard drug screening. | No THC-related monitoring required. Patients can be reassured regarding drug testing and driving. |
| Pregnancy / lactation | Insufficient data. CBD crosses the placenta in animal studies. | Contraindicated in pregnancy and lactation pending further data. Counsel women of childbearing potential. |
Prescribing Practicalities
| Item | Detail |
|---|---|
| Legal classification | Unlicensed CBPM. Schedule 2 controlled substance. Requires GMC Specialist Register prescriber. Prescribed under Human Medicines Regulations 2012, Part 10 (specials). |
| Prescription format | Private prescription on FP10PCD (controlled drug prescription form). Must include prescriber's GMC number, patient details, product name "SM32300 300 mg softgels", quantity, directions, and prescriber signature. |
| MDT requirement | NHS England guidance: decision to prescribe should be agreed by the multidisciplinary team. Private clinics: follow individual clinic governance procedures. |
| Dispensing | Via specialist CBPM pharmacies holding MHRA Specials licence and Home Office Schedule 2 import licence. SM32300 is dispensed in 14-count (trial) or 28-count (continuation) packs. |
| Storage | Store below 25°C. Protect from light. Schedule 2 controlled drug storage requirements apply at pharmacy (CD cabinet). |
| Patient counselling | Advise patients to take with food. Explain softgel format (swallow whole, do not chew). Reassure that SM32300 is THC-free and will not cause intoxication or positive drug test. Counsel on somnolence risk and driving. |
| Follow-up | Review at 2 weeks (initial tolerability). Dose adjustment at 4 weeks if needed. Quarterly review per MCCS Good Practice Guidelines. Symptom-specific PROMs (GAD-7 for anxiety, PCL-5 for PTSD, ISI for insomnia, PANSS for psychosis). |
| Patient price | 14-day trial pack (14 softgels): £79. 28-day continuation (28 softgels): £149/month. CBD cost: £17.74/g -- substantially below UK prescription CBD oils (£45-100/g). |
Key Clinical Evidence Summary
| Study | Design | Finding | Relevance |
|---|---|---|---|
| NWPT Phase 1 (2024) | n=14, crossover, SM32300 vs Epidyolex | Zero GI AEs at 600-900 mg. Enhanced plasma AUC. Reduced variability. No SAEs. | Safety and PK foundation for all prescribing. |
| McGuire 2018 Am J Psychiatry | n=88, RCT, 1000 mg CBD adjunctive to AP in schizophrenia | Significant improvement in PANSS positive (p=0.019) and CGI-I (p=0.018). | Supports 600-900 mg SM32300 adjunctive in schizophrenia. |
| Leweke 2012 Transl Psychiatry | n=42, RCT, CBD vs amisulpride in acute schizophrenia | CBD comparable to amisulpride on PANSS. Zero EPS. Anandamide elevation correlated with improvement. | Supports CBD monotherapy in schizophrenia. Confirms anandamide mechanism. |
| Bhattacharyya 2024 World Psychiatry | RCT, 600 mg CBD 21 days, CHR-P | Significant reduction in CAARMS total, negative symptoms, distress (p<0.05). PANSS total p=0.042. | Supports 300-600 mg SM32300 in CHR-P. |
| Han 2024 Psychiatry Res | Meta-analysis, 8 RCTs, 316 patients, anxiety | Hedges' g = -0.92 (substantial effect for CBD on anxiety). | Supports 300-600 mg SM32300 in GAD/SAD. |
| Gruber 2025 Biomedicines | Open-label, n=12 GAD, 30 mg CBD/day, 6 wks (Harvard/McLean) | Significant BAI, STAI improvement in first week. Improved mood, sleep, cognition. | Even low-dose CBD effective in GAD. SM32300 300 mg offers higher exposure. |
| Santos da Silva 2025 Sleep Med Rev | Meta-analysis, 6 RCTs, 1,077 patients, sleep | Cannabinoids improved sleep quality vs placebo. SMD 0.53 (p=0.04). | Supports 300 mg SM32300 for insomnia. |
| Wang 2025 J Clin Sleep Med | RCT, n=125, 300 mg CBD/day, 4 wks, insomnia | Increased SWS + REM by up to 48 min/night. No adverse events. | Directly supports 300 mg SM32300 dosing for insomnia. |
| Chesney 2020 Neuropsychopharm | Meta-analysis, 12 RCTs, n=803, CBD AEs | Diarrhoea = only significant AE in non-epilepsy populations. SM32300 eliminates this. | SM32300's zero GI AE profile is a formulation breakthrough. |
Quick Reference: Dosing by Indication
| Indication | Starting | Target | Softgels/Day | Monthly Cost | Key Evidence | Titration Notes |
|---|---|---|---|---|---|---|
| Insomnia | 300 mg | 300 mg | 1 | £149 | Wang 2025 (n=125, +48 min SWS+REM). Santos da Silva meta (SMD 0.53). | Take 1-2 hrs before bed. Most patients respond at 300 mg. Increase to 600 mg only if needed after 2 weeks. |
| Anxiety (GAD/SAD) | 300 mg | 300-600 mg | 1-2 | £149-298 | Han 2024 (g=-0.92). Gruber 2025 (n=12, sig. BAI). | Start 300 mg AM. If partial response at 2-4 wks, add PM dose (600 mg BID). |
| PTSD | 300 mg | 300 mg | 1 | £149 | Bolsoni 2022 (300 mg, sig. VAMS). NWPT Phase 2 protocol: 300 mg. | AM dosing. Can combine with trauma-focused therapy (PE/CPT). |
| Chronic pain (THC-intolerant) | 300 mg | 300-600 mg | 1-2 | £149-298 | P21 real-world data. TRPV1/adenosine mechanism. | Titrate based on pain scores. Split BID for 600 mg. |
| Schizophrenia (adjunctive to AP) | 300 mg | 600-900 mg | 2-3 | £298-447 | McGuire 2018 (1000 mg std ≈ 600-900 SM32300). Leweke 2012. | Titrate over 2 wks: 300→600→900. Monitor LFTs if on valproate. Do not discontinue antipsychotic. |
| CHR for psychosis | 300 mg | 300-600 mg | 1-2 | £149-298 | Bhattacharyya 2024 (600 mg, sig. CAARMS/PANSS). | Consider within specialist early intervention service. Monitor conversion risk. |
| Epilepsy (beyond NHS) | 300 mg | 600-900 mg | 2-3 | £298-447 | Epidyolex data (10-20 mg/kg). SM32300 bioequivalent at lower dose. | Titrate slowly. Monitor AED levels (clobazam, valproate). LFTs at baseline, 1m, 3m. |
Important: SM32300 is an unlicensed medicine. It has not received MHRA marketing authorisation. This document is provided for healthcare professional information only and does not constitute promotion of an unlicensed medicine to the public. Prescribing decisions are the sole responsibility of the treating specialist. Clinical claims are based on NWPT's proprietary Phase 1 data and published peer-reviewed literature as cited. Full Phase 1 data available under NDA from NW PharmaTech Ltd.
NW PharmaTech Ltd | 5 Wisely Court, 37 Beaufort Gardens, London SW3 1PW | nwpharmatech.com | March 2026